Condensed Consolidated Statements of Operations - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jun. 30, 2024 |
Jun. 30, 2023 |
Jun. 30, 2024 |
Jun. 30, 2023 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Revenues | ||||||
| Revenues | $ 163,163 | $ 141,237 | $ 377,258 | $ 241,959 | $ 731,493 | $ 8,939 |
| Cost of revenues | 29,665 | 25,592 | 50,460 | 49,345 | 154,900 | 4,089 |
| Cost of revenues - related party | 63,706 | 28,515 | 109,608 | 48,285 | 145,092 | |
| Gross profit | 69,792 | 87,130 | 217,190 | 144,329 | 431,501 | 4,850 |
| Operating expenses | ||||||
| General and administrative expenses | 850,704 | 567,655 | 1,622,662 | 1,951,614 | 3,319,417 | 1,643,572 |
| Salary and benefits | 259,105 | 374,396 | 552,314 | 396,094 | 977,890 | |
| Advertising and marketing | 229,244 | 797,263 | 1,081,627 | 912,997 | 2,097,505 | 352,860 |
| Investor relations | 40,000 | 90,500 | 183,000 | 519,465 | 1,100,465 | |
| Stock based compensation | 859,380 | 549,574 | 1,313,845 | 1,215,542 | 2,155,114 | |
| Total operating expenses | 2,238,433 | 2,379,388 | 4,753,448 | 4,995,712 | 9,650,391 | 1,996,432 |
| Loss from operations | (2,168,641) | (2,292,258) | (4,536,258) | (4,851,383) | (9,218,890) | (1,991,582) |
| Other expense | ||||||
| Other income | (6,473) | |||||
| Imputed interest - related party | (8,233) | (6,473) | 6,473 | |||
| Interest expense - amortization on discount | 222,678 | 222,678 | ||||
| Total other expense | 222,678 | (8,233) | 222,678 | (6,473) | (6,473) | 6,473 |
| Loss before income taxes | (2,391,319) | (2,284,025) | (4,758,936) | (4,844,910) | (9,212,417) | (1,998,055) |
| Income taxes | ||||||
| Net loss | (2,391,319) | (2,284,025) | (4,758,936) | (4,844,910) | (9,212,417) | (1,998,055) |
| Net loss attributed to non-controlling interest | (340) | (376) | ||||
| Net loss attributed to Mangoceuticals, Inc. | $ (2,390,979) | $ (2,284,025) | $ (4,758,560) | $ (4,844,910) | $ (9,212,417) | $ (1,998,055) |
| Basic and diluted loss per share | ||||||
| Basic loss per share | $ (0.09) | $ (0.14) | $ (0.19) | $ (0.33) | $ (0.57) | $ (0.19) |
| Diluted loss per share | $ (0.09) | $ (0.14) | $ (0.19) | $ (0.33) | $ (0.57) | $ (0.19) |
| Weighted average number of shares outstanding | ||||||
| Basic | 26,099,532 | 15,772,348 | 24,577,289 | 14,500,230 | 16,113,029 | 10,798,083 |
| Diluted | 26,099,532 | 15,772,348 | 24,577,289 | 14,500,230 | 16,113,029 | 10,798,083 |
| X | ||||||||||
- Definition Imputed interest related party. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Investor relations. No definition available.
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Costs of sales and operating expenses for the period incurred from transactions with related parties. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for employee benefit and equity-based compensation. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The total expense recognized in the period for promotion, public relations, and brand or product advertising. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|